Skip to content

Incorporating Healthy Living Strategies to Aid in Recovery After Acute Pulmonary Embolism

Recovery After Acute Pulmonary Embolism

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06784492
Acronym
ERASE-PE
Enrollment
100
Registered
2025-01-20
Start date
2025-02-27
Completion date
2027-12-01
Last updated
2026-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pulmonary Embolism

Keywords

Recovery acute pulmonary embolism, Six minute walk, Cardiac Effort, actigraphy

Brief summary

The purpose of the ERAsE-PE study is to determine whether two different healthy living strategies (along with anticoagulation) might aid in recovery after a patient is hospitalized for pulmonary embolism. Specifically, Investigators will compare changes in Cardiac Effort (#heart beats used during the 6-minute walk test/walk distance) measured after an 8-week program.

Interventions

BEHAVIORALHealthy Living Intervention-1

Participants will receive a text or email each day with instructions about a healthy intervention.

BEHAVIORALHealthy Living Intervention-2

Participants will receive a text or email each day with instructions about a healthy intervention.

Sponsors

University of Rochester
Lead SponsorOTHER
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. English speaking (\>18 years old). Daily messages will be sent in English. 2. Acute PE with at least one of the following: 1. any right ventricular enlargement or dysfunction on echocardiogram; 2. CT Angiogram reporting any right ventricular enlargement; or 3. elevated cardiac biomarker (NT-pro BNP or troponin above baseline). Criteria for enrollment will be included on source document. 3. Rate controlled atrial arrythmias (resting heart rate \<110 beats/m) are eligible for enrollment. This includes atrial fibrillations. This is standard of care management for atrial fibrillation. 4. Subjects do need to take prescribed anticoagulation.

Exclusion criteria

1. Pregnancy. 2. Cardiac Effort \>3.5 beats/m during 6MWT. 3. Resting tachycardia \>110 beats/m at hospital discharge. 4. Chronic Thromboembolic Pulmonary Hypertension 5. Systolic blood pressure \>180 mmHg at hospital discharge. 6. Inability to walk. 7. Estimated prognosis \<12 months at the time of discharge due to underlying co-morbidities (e.g., cancer). 8. Advanced neurologic disease and would not be able to comply with the messages. 9. Lack of access to email or text messaging 10. Inability or unwillingness to follow daily instructions.

Design outcomes

Primary

MeasureTime frameDescription
Mean change in cardiac effortBaseline and 3 monthsChange in cardiac effort is measured as the number of heart beats used during the 6-minute walk test.

Secondary

MeasureTime frameDescription
Mean number of health care visits (Health Care Utilization)3 monthsSubject medical records will be reviewed to determine the number of utilizations.
Mean change in Pulmonary Embolism Quality of Life Questionnaire (PEQOL) Scorebaseline and 3 monthsThe pulmonary embolism quality of life questionnaire ranges from 1 to 27, with higher scores indicating worse outcomes.
Mean change in 6 minute walk distancebaseline and 3 months
Mean change in activity as measured by Actigraphbaseline and 3 monthsThe Actigraph triaxial accelerometer will be used to monitor the amount of activity taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the amount of activity.
mean change in diagnosesbaseline and month 3Investifators will sum up the number of post-PE syndrome and CTEPH diagnoses and report the mean change in the sum between baseline and month 3.

Countries

United States

Contacts

CONTACTDaniel J Lachant, DO
daniel_lachant@urmc.rochester.edu5852769357

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 9, 2026